Bio-Connect offers one of the most comprehensive portfolios of antibodies worldwide.
Specialists in antibody sequencing, engineering, and recombinant manufacturing.
Absolute Antibody was founded in 2012 with a vision to make engineered recombinant antibodies accessible to all, and they remain the only company 100% focused on recombinant antibody technology. Though recombinant antibodies are standard in the pharmaceutical industry, these antibodies have not been as widely available for diagnostics or research. This is starting to change, however, due to the many advantages recombinant antibodies offer over traditional hybridoma-produced monoclonal antibodies.
In 2022, they became part of Absolute Biotech, a new company that unites multiple life science brands into one organization specializing in antibody reagents and services.
Bio-Connect Life Sciences supplies all their products in the Benelux. If you have any questions, please contact the helpdesk.
The vast majority of reagent monoclonal antibodies are generated from hybridomas, immortal antibody-producing cells created by fusing a tumor (myeloma) cell with an antibody-producing B cell from an immunized animal. However, hybridomas suffer from many limitations. They can undergo genetic drift, leading to batch-to-batch variability; they can be genetically unstable and stop expressing the antibody; and more than 30% of hybridomas contain additional antibody genes, meaning they are not actually monoclonal.
In contrast, recombinant antibodies are manufactured using synthetic genes expressed in a defined in vitro cell line. They offer a variety of benefits compared to traditional hybridoma-produced antibodies.
We gladly support you by keeping you updated on our latest products and the developments around our services.